Iovance Biotherapeutics said June 2026 revenue guidance is $86 million to $88 million, up from the company’s earlier full-year outlook framework that points to $350 million to $370 million for 2026. The company also said quarterly revenue growth was running at roughly 45% year over year in the first quarter of 2026.
Cash stood at about $319 million as of March 31, 2026, with management saying that balance gives the company runway into 2028. Gross margin in the first quarter of 2026 was 41%, though the company said that figure was affected by non-recurring, one-time costs.
On the commercial side, Iovance said it had more than 90 authorized treatment centers as of May 7, 2026, including centers in final stages of readiness or soon to be authorized. That compares with a smaller earlier footprint as the company continues building out its network. More than 1,500 patients have now been treated with commercial and clinical Iovance TIL products across the U.S., Canada and Australia.
For Amtagvi in previously treated advanced melanoma, the company highlighted a 31.4% objective response rate, 19.7% overall survival and 36.5-month median duration of response at five years of follow-up. In real-world use, it cited a 52% response rate in patients with two or fewer prior lines of therapy, versus 33% in patients with three or more prior lines. A separate real-world dataset showed a 44% response rate overall and a 73% disease control rate.
Iovance also said its manufacturing facility can support up to 5,000 patients a year across North America, Europe and APAC. The company’s pipeline includes a frontline advanced melanoma program, a post-chemo and anti-PD-1 NSCLC program, and a post-chemo advanced soft tissue sarcoma study, while it is also developing next-generation TIL therapies. As a result of these announcements, the company's shares have moved 8.56% on the market, and are now trading at a price of $4.31. For the full picture, make sure to review IOVANCE BIOTHERAPEUTICS, INC.'s 8-K report.
